5 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman

2. Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)

Edelman’s Stake Value: $188,682,000
Percentage of Joseph Edelman’s 13F Portfolio: 2.37%
Number of Hedge Fund Holders: 48

Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) is a bioprocessing company that focuses on the diagnosis, development, and marketing of medicines. It was founded in 2005 and is placed second on the list of 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. Horizon stock has returned 65.72% to investors over the course of the past 12 months. 

On June 21, Arrowhead Pharmaceuticals and Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) collaborated for ARO-XDH. It is a possible treatment for people with severe gout conditions.  Arrowhead will receive as much as $700 million under the deal. On June 23, the company reported positive results from its AROHSD1001, that will treat patients with liver diseases. While on March 22, Morgan Stanley analyst David Risinger initiated coverage on Horizon Therapeutics with an “Overweight” rating and set the price target at $103.00. 

Perceptive Advisors owns 2.05 million shares worth $188.68 million in the first quarter of 2021. Out of the hedge funds being tracked by Insider Monkey, VenBio Select Advisor is a leading shareholder in Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) with 9 million shares worth $828.36 million.

Carillon Tower Advisers, in their Q1 2021 investor letter, mentioned Horizon Therapeutics Public Limited Company (NASDAQ: HZNP). Here is what the fund said:

“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing of late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product Tepezza, which is used in the treatment of thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”